Drug Trial Radar · NCT04278768
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
366
Planned (sponsor's estimate)
Start
Jul 6, 2020
Primary completion
Apr 1, 2026
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- Curis, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML with spliceosome mutations of splicing factor 3B subunit 1 (SF3B1) or U2AF1 * R/R hrMDS with spliceosome mutations of SF3B1 or U2 small nuclear RNA auxiliary factor 1 (U2AF1) * Number of pretreatments: 1 or 2 The Phase 2a Dose Expansion will be in 3 Cohorts of patients: 1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor; 2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; and 3. R/R hrMDS (Revised International Prognostic Scoring System \[IPSS-R\] score \> 3.5) with spliceosome mutations of SF3B1 or U2AF1. All patients above have had ≤ 2 lines of prior systemic anticancer treatment. In previous versions of this protocol there was a Phase 1b portion of the study, in which patients with AML or hrMDS received CA-4948 in combination with venetoclax. This part of the study is no longer open for enrollment.
Conditions
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
Interventions
EmavusertibDrug
Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
VenetoclaxDrug
Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level. This arm of the study has been closed to enrollment.
EmavusertibDrug
Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine Maximum Tolerated Dose (MTD) of emavusertib (CA-4948) monotherapy (Phase 1)Time frame: 28 days
- Determine the Recommended Phase 2 Dose (RP2D) of emavusertib monotherapy (Phase 1)Time frame: 24 months
- Determine Maximum Tolerated Dose (MTD) of emavusertib in combination with venetoclax (Phase 1b)Time frame: 28 days
- Determine the Recommended Phase 2 Dose (RP2D) of emavusertib in combination with venetoclax (Phase 1b)Time frame: 24 months
- To assess anti-cancer activity (Phase 2a - AML patients)Time frame: 24 months
- To assess anti-cancer activity (Phase 2a - hrMDS patients)Time frame: 24 months
- To assess safety (Phase 1b)Time frame: 24 months
Locations
32 sites in 8 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska
University of Rochester Medical Center
Rochester, New York
Albert Einstein Medical College
The Bronx, New York
Novant Health Hematology - Forsyth
Winston-Salem, North Carolina
The Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio
The University of Texas MD Anderson Cancer Center
Houston, Texas
Vseobecna Fakultni nemocnice v Praze
Prague, Czechia
Service d'hématologie clinique CHU de Nice
Nice, France
APHP - Sorbonne Universite
Paris, France
APHP - Hopital Saint Louis
Paris, France
Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin
Düsseldorf, Germany
Universitätsklinikum Hamburg-Eppendorf (UKE)
Hamburg, Germany
Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I
Leipzig, Germany
Klinikum rechts der Isar der Technischen Universitat Munchen
München, Germany
Universitatsklinikum Munster
Münster, Germany
Soroka University MC
Beersheba, Israel
Edith Wolfson Medical Center
Holon, Israel
Hadassah University MC
Jerusalem, Israel
Azienda Ospedaliera Santa Croce e Carle
Cuneo, Italy
Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, Italy
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
Gdansk, Poland
University Hospital in Krakow
Krakow, Poland
Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)
Barcelona, Spain
Hospital Universitaro del a Princesa
Madrid, Spain
MD Anderson Cancer Center Madrid
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.